Alessandra Lami, Andra Catalina Manta, Veronica Amati, Stefania Alvisi, Maurizio Baldassarre, Alessia Carli, Giada Lucchetta, Renato Seracchioli, Maria Cristina Meriggiola
{"title":"Topical high concentration oxygen with hyaluronic acid: A safe and effective treatment for vaginal atrophy and sexual function improvement.","authors":"Alessandra Lami, Andra Catalina Manta, Veronica Amati, Stefania Alvisi, Maurizio Baldassarre, Alessia Carli, Giada Lucchetta, Renato Seracchioli, Maria Cristina Meriggiola","doi":"10.1177/20533691241307804","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Genitourinary syndrome of menopause (GSM) is a condition affecting many postmenopausal women. Among the available treatments, the vaginal natural oxygenation device (VNOD) is a new promising option.</p><p><strong>Aim: </strong>To evaluate the safety and the effectiveness of vaginal high concentration (HC) oxygen (O<sub>2</sub>) and hyaluronic acid (HA) in postmenopausal women with vaginal atrophy (VA).</p><p><strong>Methods: </strong>Study 1: Ten subjects received HA and O<sub>2</sub> at a concentration of 21% (sham group) and ten at 95% (treatment group). All subjects completed five sessions of VNOD. Evaluations and questionnaires were completed at baseline, before each session and at one-month follow-up: Visual Analogue Scale, Vaginal Health Index (VHI), Vaginal Maturation Value (VMV), Menopause Quality Of Life (MeNQoL), Female sexual function index (FSFI) and Female sexual distress scale (FSDS). Study 2: 52 postmenopausal women with VA completed the same protocol of study 1 with HC O<sub>2</sub> and HA.</p><p><strong>Results: </strong>Treatment was well-tolerated. In study 1, in the treatment group we recorded significant improvements in VHI score (<i>p</i>-value 0.001), VMV (<i>p</i>-value 0.005) and in the psychosocial, physical and sexual domains of the MeNQoL compared to sham group. In study 2, all women experienced a significant improvement in VHI (<i>p</i>-value <0.001), FSFI total score (<i>p</i>-value 0.007), desire (<i>p</i>-value 0.004), lubrication (<i>p</i>-value 0.006), satisfaction (<i>p</i>-value 0.042), pain (<i>p</i>-value 0.001) domains, FSDS score (<i>p</i>-value 0.003) and MeNQoL sexual domain (<i>p</i>-value <0.001).</p><p><strong>Conclusion: </strong>The preliminary results of this study suggest that VNOD is a safe and effective treatment for VA in postmenopausal women, and improves sexual function.</p>","PeriodicalId":52104,"journal":{"name":"Post reproductive health","volume":" ","pages":"20533691241307804"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Post reproductive health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20533691241307804","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Genitourinary syndrome of menopause (GSM) is a condition affecting many postmenopausal women. Among the available treatments, the vaginal natural oxygenation device (VNOD) is a new promising option.
Aim: To evaluate the safety and the effectiveness of vaginal high concentration (HC) oxygen (O2) and hyaluronic acid (HA) in postmenopausal women with vaginal atrophy (VA).
Methods: Study 1: Ten subjects received HA and O2 at a concentration of 21% (sham group) and ten at 95% (treatment group). All subjects completed five sessions of VNOD. Evaluations and questionnaires were completed at baseline, before each session and at one-month follow-up: Visual Analogue Scale, Vaginal Health Index (VHI), Vaginal Maturation Value (VMV), Menopause Quality Of Life (MeNQoL), Female sexual function index (FSFI) and Female sexual distress scale (FSDS). Study 2: 52 postmenopausal women with VA completed the same protocol of study 1 with HC O2 and HA.
Results: Treatment was well-tolerated. In study 1, in the treatment group we recorded significant improvements in VHI score (p-value 0.001), VMV (p-value 0.005) and in the psychosocial, physical and sexual domains of the MeNQoL compared to sham group. In study 2, all women experienced a significant improvement in VHI (p-value <0.001), FSFI total score (p-value 0.007), desire (p-value 0.004), lubrication (p-value 0.006), satisfaction (p-value 0.042), pain (p-value 0.001) domains, FSDS score (p-value 0.003) and MeNQoL sexual domain (p-value <0.001).
Conclusion: The preliminary results of this study suggest that VNOD is a safe and effective treatment for VA in postmenopausal women, and improves sexual function.
期刊介绍：
Post Reproductive Health (formerly Menopause International) is a MEDLINE indexed, peer reviewed source of news, research and opinion. Aimed at all those involved in the field of post reproductive health study and treatment, it is a vital resource for all practitioners and researchers. As the official journal of the British Menopause Society (BMS), Post Reproductive Health has a broad scope, tackling all the issues in this field, including the current controversies surrounding postmenopausal health and an ageing and expanding female population. Initially this journal will concentrate on the key areas of menopause, sexual health, urogynaecology, metabolic bone disease, cancer diagnosis and treatment, recovering from cancer, cardiovascular disease, cognition, prescribing, use of new hormone therapies, psychology, the science of ageing, sociology, economics, and quality of life. However as a progressive and innovative journal the Editors are always willing to consider other areas relevant to this rapidly expanding area of healthcare.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
